The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon–driven, functional genomic mouse model of medulloblastoma with ‘humanized’ in vivo therapy (microneurosurgical tumour resection followed by multi-fractionated, image-guided radiotherapy). Genetic events in recurrent murine medulloblastoma exhibit a very poor overlap with those in matched murine diagnostic samples (<5%). Whole-genome sequencing of 33 pairs of human diagnostic and post-therapy medulloblastomas demonstrated substantial genetic divergence of the dominant clone after therapy (<12% diagnostic events were retained at recurrence). In both mice and humans, the dominant clone at recurrence arose through clonal selection of a pre-existing minor clone present at diagnosis. Targeted therapy is unlikely to be effective in the absence of the target, therefore our results offer a simple, proximal, and remediable explanation for the failure of prior clinical trials of targeted therapy.

Nature doi: 10.1038/nature16478

Nature Latest Research

 
STRATEGIES FOR A COMPANY’S INTELLECTUAL PROPERTY. IP protection is a part of your business strategy and matches your commercial goals. A simple IP strategy is to protect your product and service by getting patent, trademark and copyright certificates.
 

U.S. COMPANY REGISTRATION. We help our foreign clients with registering U.S. business to support moving their innovations to U.S. market. We assist in navigating the process of setting up a new business and support while it grows.

EXHIBITION PRESENTATION. We are working with major organizers of international conferences in USA. We discuss in advance all possible discounts and available places for your expositions.